Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Capital Markets

<p>In our first insight, we covered the company's background, particularly its management team and its product pipeline.In this insight, we will discuss valuation and deal specific details. </p><h2>Thoughts on Valuation</h2><p>Given the limited drug candidates product pipeline and lack of income, we think the SOTP based on risk adjusted NPV valuation is a suitable valuation method for Zai Lab. Our valuation will encompass the following assumptions for each product:</p><ul><li>Annual case: We will take this number from the…</li></ul>

In our first insight, we covered the company's background, particularly its management team and its product pipeline.In this insight, we will discuss valuation and deal specific details. Thoughts on ValuationGiven the limited drug candidates product pipeline and lack of income, we think the SOTP based on risk adjusted NPV valuation is a suitable valuation method for Zai Lab. Our valuation will encompass the following assumptions for each product:Annual case: We will take this number from the…

Zai Lab IPO: Thoughts on Valuation, Risks and Upsides (Part 2)

United States

Paratek Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the development and commercialization of antibiotics. The Company develops medicine for serious community-acquired bacterial infections. Paratek Pharmaceuticals' products treat patients in both the community and hospital setting.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Paratek Pharmaceuticals (PRTK US)

Zai Lab IPO: Thoughts on Valuation, Risks and Upsides (Part 2)

In our first insight, we covered the company's background, particularly its management team and its product pipeline.In this insight, we will...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)